GlobalData analyst Dr Andrew S Thompson expects the deal to prompt a "shuffle" in Thermo Fisher’s life sciences unit.

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, ...

Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides ...

Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on ...

Thermo Fisher Scientific has a market capitalization of about $203.5 billion. Shares (NYSE: TMO) at midday Wednesday were trading around $532, which is near the bottom of their 52-week range.

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...

Well, welcome to the 45th Annual TD Cowen Healthcare Conference. I'm Dan Brennan, follow Tools and Diagnostics. Really pleased to be joined on stage here with Marc Casper, Chairman and President of ...

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...

BofA raised the firm’s price target on Solventum (SOLV) to $85 from $80 and keeps a Neutral rating on the shares after the company agreed to ...